ERBB2 and breast carcinoma: Its protein overexpression or gene amplification has been present in around one-fifth of breast cancer cases [22], especially in HER2-enriched or HER2+ luminal B subtypes, which have a worse prognosis than their HER2-negative counterpart [23].